Outcomes of Immunotherapy in Advanced HCC: A Brazilian Multicenter Real-World Study
Brazilian Journal of Oncology · 26.06.2026 · 22 (CP)
DOI: 10.1055/s-0046-1825489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 26.06.2026. Verfasst von Cecília Freire und 10 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window) Address for correspondence Cecília Freire (ceciliasouzafreire@gmail.com)
Background
Phase III trials have demonstrated the superiority of immunotherapy-based combinations over sorafenib or lenvatinib in patients with unresectable hepatocellular carcinoma (HCC). However, the adoption of immunotherapy in routine practice is challenged by the risk of liver decompensation and adverse events (AE). Therefore, real-world data are needed.
Aim
To describe the clinical characteristics and outcomes of patients with HCC treated with immunotherapy in a real-world setting.
Methods
We analyzed a multicenter database of patients with HCC treated from 2020 to 2025. Patients who received immunotherapy-based regimens were included. Clinicopathologic characteristics were assessed for their prognostic impact on overall survival (OS). Overall response rate (ORR) and AEs were reported.
Results
A total of 228 patients were included. The median age was 70.7 years; 82.7% had Child-Pugh A and 88.1% had ECOG performance status 0–1. Viral hepatitis was the predominant etiology (32.7%), followed by metabolic-associated liver disease (20.6%). Most patients were classified as BCLC-C (72.6%), 40.7% had portal vein invasion, and 30.1% had extrahepatic metastases. The most commonly used regimen was atezolizumab plus bevacizumab (68.3%), followed by durvalumab with or without tremelimumab (20.7%), with a median treatment duration of 4.5 months. Baseline endoscopy was performed in 146 patients (64.1%), and esophageal varices were identified in 69. After a median follow-up of 8.8 months (95% CI: 2.3–13.7), the median OS was 14.5 months (95% CI: 10.7–22.4). Among response-evaluable patients (n=160), the ORR was 27.5%, and the disease control rate was 60.6%. Immune-related AEs occurred in 63 patients (8 with grade ≥3), and 14 patients experienced bleeding events (including 8 due to gastroesophageal varices). Favorable prognostic factors for OS included ALBI grade 1 (p=0.03), partial response (p 1. Our findings reinforce the applicability of immunotherapy in routine practice and highlight the prognostic role of liver function and the need to monitor AEs. Publication History Article published online: 26 June 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil Bibliographical Record Cecília Freire, Leonardo Gomes Fonseca, Marcos Lyra, Rodrigo Guedes, Mariana Bruno, Duilio Rocha, Lucila Soares, Maria de Lourdes Oliveira, Rodrigo Tancredi, Guilherme Stelko, Paulo Hoff. Outcomes of Immunotherapy in Advanced HCC: A Brazilian Multicenter Real-World Study. Brazilian Journal of Oncology 2026; 22. DOI: 10.1055/s-0046-1825489
Zitieren
APA
Freire, C., Fonseca, L. G., Lyra, M., Guedes, R., Bruno, M., Rocha, D., Soares, L., Oliveira, M. D. L., Tancredi, R., Stelko, G., & Hoff, P. (2026). Outcomes of Immunotherapy in Advanced HCC: A Brazilian Multicenter Real-World Study. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0046-1825489
Vancouver
Freire C, Fonseca LG, Lyra M, Guedes R, Bruno M, Rocha D, et al. Outcomes of Immunotherapy in Advanced HCC: A Brazilian Multicenter Real-World Study. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0046-1825489
BibTeX
@article{Freire2026,
author = {Freire, Cecília and Fonseca, Leonardo Gomes and Lyra, Marcos and Guedes, Rodrigo and Bruno, Mariana and Rocha, Duilio and Soares, Lucila and Oliveira, Maria de Lourdes and Tancredi, Rodrigo and Stelko, Guilherme and Hoff, Paulo},
title = {Outcomes of Immunotherapy in Advanced HCC: A Brazilian Multicenter Real-World Study},
journal = {Brazilian Journal of Oncology},
year = {2026},
volume = {22},
number = {CP},
doi = {10.1055/s-0046-1825489}
}
EUVIMED